Related Experiment Videos
Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative
M Havel1, F Grabenwöger, J Schneider
1Second Department of Surgery, University Hospital of Vienna, Austria.
The Journal of Thoracic and Cardiovascular Surgery
|March 1, 1994
Summary
Aprotinin significantly reduced bleeding and blood transfusion needs in patients undergoing coronary artery bypass grafting. This study found no negative impact on early graft patency in patients receiving aprotinin.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
Background:
- Coronary artery bypass grafting (CABG) is a common surgical procedure.
- Postoperative bleeding and the need for blood transfusions are significant concerns in CABG patients.
Purpose of the Study:
- To evaluate the efficacy of aprotinin in reducing postoperative bleeding and transfusion requirements after CABG.
- To assess the effect of aprotinin on early vein graft patency following CABG.
Main Methods:
- A double-blind, randomized study involving 45 male patients undergoing planned CABG.
- Patients were assigned to receive high-dose aprotinin, low-dose aprotinin, or placebo.
- Postoperative bleeding, transfusion needs, and vein graft patency (via coronary angiography) were assessed.
Main Results:
- Both high-dose and low-dose aprotinin groups showed significantly reduced postoperative bleeding compared to the placebo group (p < 0.001).
- The need for postoperative blood transfusions was significantly lower in aprotinin groups (p < 0.05).
- No significant difference in early vein graft patency was observed among the three groups.
Conclusions:
- Aprotinin effectively reduces postoperative bleeding and the requirement for blood transfusions in CABG patients.
- The use of aprotinin does not adversely affect early vein graft patency after CABG.